New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Xanax
(France) [Available]Synonyms :
alprazolam
Class :
Antianxiety agents, Benzodiazepines, Antiemetics
Brand Name :
Xanax
(France) [Available]Synonyms :
alprazolam
Class :
Antianxiety agents, Benzodiazepines, Antiemetics
AdultÂ
Dosage forms & Strengths:Â
TabletÂ
0.25mgÂ
0.5mgÂ
1mgÂ
2mgÂ
Extended-release tabletÂ
0.5mgÂ
1mgÂ
2mgÂ
3mgÂ
Orally disintegrating tabletÂ
0.25mgÂ
0.5mgÂ
1mgÂ
2mgÂ
Oral solutionÂ
1mg/mlÂ
Infusion solutionÂ
200mg/100 mlÂ
200mg/20 ml Â
400mg/40 mlÂ
400mg/200 mlÂ
A dose of 0.25-0.5 mg orally every 6 to 8 hours is indicated for 3 to 4 days
Do not outreach the drug dose to more than 4 mg/day
An immediate-release tablet of 0.5 mg is recommended orally every 8 hours for 4 days
An extended-release tablet of 0.5-1 mg orally each day. May increase the dose by 1 mg/day every 3-4 days
Average dose is 3-6 mg orally each day
An immediate-release tablet of 0.5 mg is recommended orally every 8 hours for 4 days
An extended-release tablet of 0.5-1 mg orally each day. May increase the dose by 1 mg/day every 3-4 days
Average dose is 3-6 mg orally each day
1-4 mg of alprazolam orally every 8 hours a day
alprazolam is not recommended for children below 18 yearsÂ
Refer to adult dosing for panic disorder and anxiety-related depressionÂ
Use a potent dose to prevent oversedation or ataxiaÂ
Older people sensitive to benzodiazepines should be given a reduced doseÂ
may have a decrease in excretion rate when combined with tetradecyl sulfuric acid
alprazolam: it may decrease the risk of CNS depression of mianserin
alprazolam: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
may enhance the CNS depressant effect
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the metabolism when combined
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the risk of CNS depression when combined
may have an increased risk of CNS depression when combined with alprazolam
the excretion rate of bisoxatin may be decreased with alprazolam leading to higher concentration in serum
co-adminstration of sibutramine with alprazolam may cause an increase in drowsiness, altered locomotor movement, confusion.
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
They increase the concentration of alprazolam in serum
It increases the concentration of alprazolam in serum
it increases the concentration of CYP3A4 substrates in serum
CNS depressants increase the effect of flunarizine
it increases the CNS depressing effect of other CNS depressants
it increases the CNS depressing effect of other CNS depressants
it increases the CNS depressing effect of other CNS depressants
it increases the concentration of CYP3A4 in serum
CNS depressants increase the effect of thalidomide
when both drugs are combined, there may be a decreased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of alprazolam
it increases the effect of CNS depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased effect of CNS depression when combined with Alprazolam
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
it increases the effect of CNS depressants
CNS depressants increase the effect of brexanolone
CYP3A4 inhibitors increase the concentration of carbamazepine in serum
it increases the effect of CNS depressants
it decreases the concentration of CYP3A4 substrates in serum
CYP3A4 inhibitors increase the concentration of flibanserin in serum
it increases the effect of CNS depressants
CYP3A4 inhibitors increase the concentration of midazolam in serum
CYP3A4 inhibitors increase the concentration of nimodipine in serum
it increases the effect of CNS depressants
CNS depressants increase the effect of rotigotine
CYP3A4 inhibitors increase the concentration of sirolimus in serum
CYP3A4 inhibitors increase the concentration of tacrolimus in serum alpra
it decreases the efficacy of antianxiety agents
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS depressants may enhance the CNS depressant effect of cannabinoid-Containing products
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
It may enhance sedation when combined with tramadol
It may enhance sedation when combined with a shepherd's purse
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
may enhance the concentration of serum when combined with alprazolam
alprazolam: they may diminish the serum concentration of CYP3A4 Inducers
alprazolam: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance sedation when combined with codeine
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
It may enhance sedation when combined with oxycodone
it may enhance the sedation when combined with lofexidine
The potential for increased CNS depression risk or seriousness occurs when alprazolam is used together with pinazepam
When captodiame is used together with alprazolam, There is a risk or seriousness of CNS depression is enhanced
It may diminish the metabolism when combined with nilvadipine
The potential for CNS depression may enhanced when alprazolam is used together with fencamfamin
Combining tegafur with alprazolam can reduce tegafur’s metabolism
When alprazolam is used together with medazepam, the risk or seriousness of CNS depression is enhanced
alprazolam may intensify paraldehyde's CNS depressant effects
When alprazolam is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
when alprazolam is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When domeperidone and alprazolam is used together, this leads to reduction in the domeperidone’s metabolism
When alprazolam is used together with fluconazole, this leads to reduction in the alprazolam metabolism
When chlordiazepoxide is used together with alprazolam, this leads to enhanced risk or seriousness of CNS depression
When alprazolam is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with alprazolam, this leads to enhanced risk or seriousness of CNS depression
When emylcamate is used together with alprazolam, this leads to enhanced risk or seriousness of CNS depression
When alprazolam is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When isoflurane is used together with alprazolam, this leads to enhanced risk or seriousness of CNS depression
alprazolam leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of alprazolam which leads to increased level of serum
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
alprazolam leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
alprazolam leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
alprazolam leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
When indisulam is used together with alprazolam, this leads to a reduction in alprazolam metabolism
When alprazolam is used together with oleandomycin, this leads to enhanced concentration serum of alprazolam
When alprazolam is used together with patupilone, this leads to enhanced concentration serum of alprazolam
alprazolam: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
alprazolam: it may increase the risk or severity of CNS depression
When alprazolam is used together with ridaforolimus, this leads to enhanced concentration serum of alprazolam
proquazone may slow down the rate of alprazolam excretion, which could lead to a greater serum level
clonixin may slow down the drug's elimination rate, which could lead to higher serum concentrations
flunixin may lower the excretion rate of alprazolam which could result in a raised serum level
tepoxalin may reduce the excretion rate of alprazolam, potentially resulting in elevated serum levels
the metabolism of alprazolam can be decreased when combined with fostamatinib
alprazolam: it may decrease the metabolism of gestodene
alprazolam may diminish the excretion speed of hydroxyethyl starch, potentially leading to an elevated serum level
when both drugs are combined, there may be an increased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
the effect of alprazolam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors increase the concentration of alprazolam in serum
diphenoxylate, when used with alprazolam, increases sedation
nabilone and alprazolam, when used simultaneously, both increase the sedation
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
The interaction may enhance the drug serum levels of benzodiazepine agonist hypnotics
it increases the effect of CNS depressants
may increase the sedative effect
may enhance the serum concentration of CYP3A4 inhibitors
may have an increased adverse effect when combined with olanzapine.
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
When alprazolam and acetaminophen is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and acetazolamide is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and aldesleukin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and alpelisib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and amiodarone is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and astemizole is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and berotralstat is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and bicalutamide is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and bifonazole is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and boceprevir is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and bosutinib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and bromocriptine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cabergoline is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and capsaicin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cenobamate is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and ceritinib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cerivastatin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and chloramphenicol is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cimetidine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and ciprofloxacin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and citalopram is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and clevidipine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and clofazimine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cobicistat is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and conivaptan is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and crizotinib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and curcumin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and cyclosporine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and dabrafenib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and dalfopristin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and danazol is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and dapsone is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and dasatinib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and daunorubicin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and desipramine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and desvenlafaxine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and dexamethasone is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and diazepam is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and docetaxel is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and doxorubicin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and efavirenz is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and elbasvir is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and enasidenib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and epinephrine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and ergotamine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and etoposide is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and etoricoxib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and fexinidazole is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and fosphenytoin is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and fusidic acid is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and glyburide is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and haloperidol is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and hydralazine is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and imatinib is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and isoniazid is used together, this leads to reduction in the alprazolam’s metabolism
When alprazolam and ketozolam is used together, this leads to reduction in the alprazolam’s metabolism
when combined with bacitracin, the serum level of alprazolam will increase, leading to decreased output of alprazolam from the body
sedative effects can be increased when alprazolam is administered with papaverine
metabolism of alprazolam can be reduced when combined with telaprevir
the rate of metabolism of alprazolam may be reduced
the rate of metabolism of alprazolam may be reduced
the rate of excretion of alprazolam may be reduced
the serum levels of alprazolam may be increased
the serum levels of alprazolam may be increased
the serum levels of alprazolam may be increased
the rate of excretion of alprazolam may be reduced
niflumic acid may lower the excretion rate of alprazolam, which could result in a raised serum level
the risk of adverse effects may be increased
the risk of CNS depression may be increased
alprazolam might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
alprazolam enhances the level of lithium by reducing renal clearance
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it enhances the effect of alprazolam by diminishing the metabolism
it decreases the effect of alprazolam by diminishing the metabolism
zolpidem and alprazolam increase the effect of each other by pharmacodynamic antagonism
CNS depressants increase the effect of zolpidem
Actions and Spectrum:Â
Alprazolam has rapid onset and short duration of action lasting 4-6 hours and making it a popular choice for generalized anxiety disorders.Â
1-10%Â
Drowsiness Â
Depression Â
Headache Â
Constipation Â
Diarrhea Â
Dry mouth Â
Increased salivation Â
Talkativeness Â
Incontinence Â
Respiratory depression, coma, and death.Â
Contraindication/Caution:Â
It can cause respiratory depression, severe hepatic impairment, renal impairment, depression, suicidal tendencies, substance abuse, increased sedation, and cognitive impairment in elderly patients.Â
regnancy consideration:Â Â
Benzodiazepines cross the placenta during gestation and may cause respiratory distress or sedation to the fetus. Â
Consult the physician before taking the medicationÂ
Breastfeeding warnings: lactating females should not breastfeed during the treatment.Â
Continue breastfeeding after the two half-lives of the last dose.Â
Pregnancy category:Â
Pharmacology:Â
Administration:Â
alprazolam is usually administered orally, in tablet form, with or without food. The dosage and duration of treatment depend on the patient’s medical condition, age, and response to treatment. The usual starting dose for anxiety disorders is 0.25-0.5 mg administered orally 3 times a day, with gradual dose increases as needed and tolerated up to a maximum daily dose of 4 mg.
The usual starting dose for panic disorder is 0.5 mg administered orally 3 times a day, with gradual dose increases as needed and tolerated up to a maximum daily dose of 10 mg. Elderly patients, patients with hepatic or renal impairment, and patients with other medical conditions may require lower doses of alprazolam. alprazolam should only be used for the shortest duration possible and at the lowest effective dose.
Abrupt discontinuation of the medication can lead to withdrawal symptoms, and the dose should be gradually tapered off under the guidance of a healthcare provider. alprazolam has a potential for abuse and dependence, and its use should be carefully monitored. Patients should not take more than the prescribed dose and should not share their medication with others.Â
Patient information leafletÂ
Generic Name: alprazolamÂ
Pronounced: al-prah-zoh-laamÂ
Why do we use alprazolam?Â
Alprazolam treats generalized anxiety disorder, panic disorder, insomnia and depression. It enhances the neurotransmitter GABA, reducing anxiety symptoms, and calming the brain. It also helps reduce panic attacks and associated symptoms.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
